Compare BridgeBio Pharma Inc (BBIO) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs MakeMyTrip Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.88 (market cap $16.36B), while MakeMyTrip Ltd trades at $60.39 (market cap $5.78B). The key difference: BridgeBio Pharma Inc is far larger — about 2.8× MakeMyTrip Ltd's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | MMYT | |
|---|---|---|
Market Cap | $16.36B | $5.78B |
Sector | Health | Technology |
52-Week High | $90.17 | $103.21 |
52-Week Low | $47.29 | $36.30 |
Enterprise Value | $18.14B | $6.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
MakeMyTrip (MMYT) trades at $60.30, down 1.0% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2027 earnings that beat expectations despite revenue headwinds, maintaining robust gross margins of 73.45%. Recent news highlights growth in hotels and packages segments offsetting air travel softness, with analyst consensus strongly bullish at 73% buy ratings.
The outlook remains positive with earnings momentum and diversified travel services driving growth, though elevated P/E ratio of 267 and geopolitical travel disruptions present risks. Institutional sentiment supports upside potential with 34% average price target, while balance sheet strength provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
